ALZHEON
ALZHEON, INC.
76 Investors
Biotechnology
FRAMINGHAM, MA
Alzheon, Inc. is a biotechnology company dedicated to developing innovative treatments for Alzheimer's disease. The company focuses on creating therapeutics that aim to slow or halt the progression of Alzheimer's and potentially prevent the onset of clinical symptoms.
Products & Team
ALZ-801/valiltramiprosate
Alzheimer's treatmentSeed
ALZ-801/valiltramiprosate is an oral small molecule inhibitor designed to target the neurotoxic amyloid oligomers, which are believed to play a key role in the development and progression of Alzheimer's disease.
Value Proposition
It addresses the need for easily accessible Alzheimer's treatments that can slow disease progression and potentially prevent clinical symptoms.
Pain Points
Lack of effective and accessible treatment options that can slow disease progression or prevent onset
Only oral anti-amyloid treatment in Phase 3 testingTargets formation of neurotoxic amyloid oligomersFast Track development designation by the FDA
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
FRAMINGHAM, MA
Primary headquarters
Funding History
Total Raised:
$126.3M
E
Equity Offering
February 2024
$150.0M
Target
Progress
84%Raised
$126.3M
Target
$150.0M
#000158263625000002